Last reviewed 2026-04-22 · How we verify

ARB + DMX-200

UMC Utrecht · Phase 3 active Small molecule

ARB + DMX-200 is a Angiotensin II receptor blocker (ARB) with drug delivery enhancement Small molecule drug developed by UMC Utrecht. It is currently in Phase 3 development for Hypertension (presumed primary indication based on ARB class), Cardiovascular protection in phase 3 development.

ARB + DMX-200 combines an angiotensin II receptor blocker with DMX-200, a drug delivery technology designed to enhance therapeutic efficacy and potentially reduce adverse effects.

ARB + DMX-200 combines an angiotensin II receptor blocker with DMX-200, a drug delivery technology designed to enhance therapeutic efficacy and potentially reduce adverse effects. Used for Hypertension (presumed primary indication based on ARB class), Cardiovascular protection in phase 3 development.

Likelihood of approval

56.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ARB + DMX-200
Sponsor	UMC Utrecht
Drug class	Angiotensin II receptor blocker (ARB) with drug delivery enhancement
Target	Angiotensin II type 1 receptor (AT1R)
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 3

Mechanism of action

ARBs block angiotensin II type 1 receptors to lower blood pressure and reduce cardiovascular strain. DMX-200 is a proprietary drug delivery platform from UMC Utrecht that may improve bioavailability, tissue targeting, or sustained release of the ARB component. The combination aims to optimize cardiovascular outcomes while potentially minimizing systemic side effects through targeted delivery.

Approved indications

Hypertension (presumed primary indication based on ARB class)
Cardiovascular protection in phase 3 development

Common side effects

Hyperkalemia
Dizziness
Fatigue
Hypotension

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ARB + DMX-200 CI brief — competitive landscape report
ARB + DMX-200 updates RSS · CI watch RSS
UMC Utrecht portfolio CI

Frequently asked questions about ARB + DMX-200

What is ARB + DMX-200?

ARB + DMX-200 is a Angiotensin II receptor blocker (ARB) with drug delivery enhancement drug developed by UMC Utrecht, indicated for Hypertension (presumed primary indication based on ARB class), Cardiovascular protection in phase 3 development.

How does ARB + DMX-200 work?

ARB + DMX-200 combines an angiotensin II receptor blocker with DMX-200, a drug delivery technology designed to enhance therapeutic efficacy and potentially reduce adverse effects.

What is ARB + DMX-200 used for?

ARB + DMX-200 is indicated for Hypertension (presumed primary indication based on ARB class), Cardiovascular protection in phase 3 development.

Who makes ARB + DMX-200?

ARB + DMX-200 is developed by UMC Utrecht (see full UMC Utrecht pipeline at /company/umc-utrecht).

What drug class is ARB + DMX-200 in?

ARB + DMX-200 belongs to the Angiotensin II receptor blocker (ARB) with drug delivery enhancement class. See all Angiotensin II receptor blocker (ARB) with drug delivery enhancement drugs at /class/angiotensin-ii-receptor-blocker-arb-with-drug-delivery-enhancement.

What development phase is ARB + DMX-200 in?

ARB + DMX-200 is in Phase 3.

What are the side effects of ARB + DMX-200?

Common side effects of ARB + DMX-200 include Hyperkalemia, Dizziness, Fatigue, Hypotension.

What does ARB + DMX-200 target?

ARB + DMX-200 targets Angiotensin II type 1 receptor (AT1R) and is a Angiotensin II receptor blocker (ARB) with drug delivery enhancement.

Drug class: All Angiotensin II receptor blocker (ARB) with drug delivery enhancement drugs
Target: All drugs targeting Angiotensin II type 1 receptor (AT1R)
Manufacturer: UMC Utrecht — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Hypertension (presumed primary indication based on ARB class)
Indication: Drugs for Cardiovascular protection in phase 3 development

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing